text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 103060-53-3 | Product Number: D4229


Purity: >94.0%(HPLC)(N)
6   ≥20 

*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).

Product Number D4229
Purity / Analysis Method >94.0%(HPLC)(N)
Molecular Formula / Molecular Weight C__7__2H__1__0__1N__1__7O__2__6 = 1620.69  
Physical State (20 deg.C) Solid
Storage Temperature -20°C
Condition to Avoid Heat Sensitive
CAS RN 103060-53-3
Reaxys Registry Number 8186242
PubChem Substance ID 172089104
Merck Index (14) 2823
MDL Number


Appearance White to Yellow to Orange powder to crystal
Purity(HPLC) min. 94.0 area%
Purity(with Total Nitrogen) min. 94.0 %
Properties (reference)
Maximum Absorption Wavelength 260(EtOH) nm
Solubility in water Completely soluble
Solubility (soluble in) Methanol
Solubility (very slightly) Ethanol
Related Laws: / Compliance with laws, Regulations
RTECS# HB5626000
Transport Information:
HS Number 2941900000
Studies on the Antibiotic Activity of Daptomycin

Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus

J. A. Silverman, N. G. Perlmutter, H. M. Shapiro, Antimicrob. Agents Chemother. 2003, 47, 2538.

In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains

M. J. Rybak, E. Hershberger, T. Moldovan, R. G. Grucz, Antimicrob. Agents Chemother. 2000, 44, 1062.

Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate

L. Cui, E. Tominaga, H. Neoh, K. Hiramatsu, Antimicrob. Agents Chemother. 2006, 50, 1079.

Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus

L. Friedman, J. D. Alder, J. A. Silverman, Antimicrob. Agents Chemother. 2006, 50, 2137.

Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections

J. N. Steenbergen, J. Alder, G. M. Thorne, F. P. Tally, J. Antimicrob. Chemother. 2005, 55, 283.

Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05

G. Steinkraus, R. White, L. Friedrich, J. Antimicrob. Chemother. 2007, 60, 788.

PubMed Literature

Safety Data Sheet (SDS) Search
Please select Language.

The requested SDS is not available.

• Please check that the Product Number you have entered is correct.

• If your information is correct and you are still not able to view the requested SDS,  please Contact Us for more information.

C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number is entered
Other Documents